McKechnie Duncan
SEC CIK 2062139 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| VRTX | Vertex Pharmaceuticals | EVP, Chief Commercial Off | 11.0K | — | $5.66M | 10 | 2026-01-22 | 2026-07-02 |
Most active insiders at VRTX, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | LEIDEN JEFFREY M | Executive COB, Dir | — | $60.94M |
| 2 | Sachdev Amit | EVP Chief Patient, Ext Af Off | — | $28.38M |
| 3 | Kewalramani Reshma | CEO, Pres, Dir | — | $19.74M |
| 4 | Bozic Carmen | EVP, CMO | — | $11.31M |
| 5 | WAGNER CHARLES F JR | EVP, CO, FO | — | $10.78M |
| 6 | Tatsis Ourania | EVP, Chief Reg, Quality Off | — | $6.51M |
| 7 | McKechnie Duncan | EVP, Chief Commercial Off | — | $5.66M |
| 8 | Biller Jonathan | EVP, CLO | — | $4.08M |
| 9 | Atkinson Edward Morrow III | EVP, Chief Technical Ops. Off | — | $3.60M |
| 10 | Bunnage Mark E. | EVP, CSO | — | $3.00M |
Transactions 10
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| T | 2026-07-07 16:08 | 2026-07-02 | VRTX | Vertex Pharmaceuticals | McKechnie Duncan | EVP, Chief Commercial Off | S - Sale | $519.00 | -1,541 | 11.0K | -12% | -$799.8K |
| 2026-03-13 | 2026-03-11 | VRTX | Vertex Pharmaceuticals | McKechnie Duncan | EVP, Chief Commercial Off | S - Sale | $498.42 | -2,633 | 12.5K | -17% | -$1.31M | |
| 2026-03-06 | 2026-03-04 | VRTX | Vertex Pharmaceuticals | McKechnie Duncan | EVP, Chief Commercial Off | S - Sale | $475.30 | -2,437 | 15.1K | -14% | -$1.16M | |
| M | 2026-02-26 | 2026-02-25 | VRTX | Vertex Pharmaceuticals | McKechnie Duncan | EVP, Chief Commercial Off | S - Sale | $487.65 | -4,910 | 20.0K | -20% | -$2.39M |
| 2026-02-26 | 2026-02-24 | VRTX | Vertex Pharmaceuticals | McKechnie Duncan | EVP, Chief Commercial Off | F - Tax | $485.11 | -873 | 22.5K | -4% | -$423.5K | |
| 2026-02-19 | 2026-02-17 | VRTX | Vertex Pharmaceuticals | McKechnie Duncan | EVP, Chief Commercial Off | F - Tax | $483.75 | -1,148 | 23.3K | -5% | -$555.3K | |
| 2026-02-19 | 2026-02-17 | VRTX | Vertex Pharmaceuticals | McKechnie Duncan | EVP, Chief Commercial Off | A - Grant | $0.00 | +4,962 | 24.5K | +25% | $0 | |
| 2026-02-18 | 2026-02-13 | VRTX | Vertex Pharmaceuticals | McKechnie Duncan | EVP, Chief Commercial Off | F - Tax | $487.76 | -2,283 | 19.5K | -10% | -$1.11M | |
| 2026-02-12 | 2026-02-10 | VRTX | Vertex Pharmaceuticals | McKechnie Duncan | EVP, Chief Commercial Off | F - Tax | $468.41 | -1,127 | 21.8K | -5% | -$527.9K | |
| M | 2026-01-26 | 2026-01-22 | VRTX | Vertex Pharmaceuticals | McKechnie Duncan | EVP, Chief Commercial Off | A - Grant | $0.00 | +6,800 | 20.9K | +48% | $0 |
Purchase Sale Sale after option exercise All abbreviations